alexa
Reach Us +32-28-08-6657

GET THE APP

Editorial Note on Therapeutic Measures of Coronavirus
ISSN: 2476-2024

Diagnostic Pathology: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Editorial   
  • Diagn Pathol Open S3: e003
  • DOI: 10.4172/2476-2024.s3.e003

Editorial Note on Therapeutic Measures of Coronavirus

Maria Teresa Mascellino*
Department of Infectious Diseases, Sapienza University of Rome, Italy
*Corresponding Author: Maria Teresa Mascellino, Department of Infectious Diseases, Sapienza University of Rome, Italy

Received Date: Jun 16, 2021 / Accepted Date: Jun 30, 2021 / Published Date: Jul 06, 2021

Keywords: Therapy; Coronavirus; COVID-19; SARS-CoV-2

Editorial Note

The continuous pandemic of COVID sickness 2019 (COVID-19) brought about by the extreme intense respiratory disorder COVID-19 (SARS-CoV-2) has conveyed a genuine general wellbeing intimidation worldwide with a great many individuals in danger in a developing number of nations. However there are no clinically endorsed antiviral medications and antibodies for COVID-19, endeavours are progressing for clinical preliminaries of a few known antiviral medications, their mix, just as improvement of immunizations in patients with affirmed COVID-19.

This survey centres on the furthest down the line ways to deal with diagnostics and treatment of COVID-19. We have summed up ongoing advancement on the customary therapeutics like antiviral medications, immunizations, against SARS-CoV-2 immunizer medicines, and healing plasma treatment which are presently under broad examination and clinical preliminaries for the treatment of COVID-19. The improvements of nanoparticle-based remedial and demonstrative methodologies have been likewise examined for COVID-19. We have surveyed late writing information on this subject and made a rundown of current turn of events and future viewpoints.

Recently arising infection sicknesses have become a significant general wellbeing danger all throughout the planet as of late. During the most recent twenty years, episodes of a few viral infections have been accounted for including the serious intense respiratory condition COVID (SARS-CoV) in 2002, H1N1 flu in 2009, the Middle East respiratory disorder COVID (MERS-CoV) in 2012, Ebola infection illness (EVD) in 2013, and Zika infection in 2015. The latest and continuous viral sickness brought about by the novel COVID has seriously undermined general wellbeing around the world. The episode of novel COVID was at first answered to the World Health Organization (WHO) on December 31, 2019.

On January 12, 2020, WHO assigned this infection as novel COVID "2019-nCoV", and later, it was named as the extreme intense respiratory condition COVID 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV) due to its comparability with the past SARS-CoV. Human-to-human transmission rate is higher for SARS-CoV-2 than that of SARS-CoV infection, the death pace of COVID-19 sickness is a lot of lower than that of SARS-CoV contamination. While all COVIDs trouble the respiratory parcel, SARS-CoV-2 infection furthermore likewise influences the heart, gastrointestinal framework, liver, kidney, and the focal sensory system in the long run prompting multi-organ disappointment.

While critical endeavours have been made in late time in the improvement of novel remedial and analytic methodologies for COVID-19 illness, still numerous inquiries and difficulties, for example, level of affectability and particularity of serological tests for the recognition of hostile to SARS-CoV-2 neutralizer in clinical example, regardless of whether the presence of such antibodies can deliver insusceptibility to this COVID and so forth, still need to be tended to. Although few antiviral therapeutics such as remdesivir, umifenovir, favipiravir, and ribavirin were evaluated in clinical trials and showed some positive results, still more evidences are needed for their successful clinical use against this disease. Until this point, there is no clinically supported therapeutics and immunizations for COVID-19. Subsequently, early finding like testing of suggestive and asymptomatic people and their nearby contacts by contact following, isolate of the contaminated people, and compelling steady treatment of SARS-CoV-2-tainted people are the way to forestall extra transmission and control this sickness until any clinically supported antiviral therapeutics or potentially immunizations for COVID-19 is accessible on the lookout.

Citation: Mascellino MT ( 2021) Editorial N ote on Therapeutic Measures of Coronavirus. Diagnos Pathol Open S3: e003. DOI: 10.4172/2476-2024.s3.e003

Copyright: © 2021 Mascellino MT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 279
  • [From(publication date): 0-0 - Sep 24, 2021]
  • Breakdown by view type
  • HTML page views: 125
  • PDF downloads: 154
Top